Avadel Pharmaceuticals (AVDL)
NASDAQ: AVDL
· Real-Time Price · USD
13.69
0.19 (1.41%)
At close: Aug 15, 2025, 3:59 PM
13.64
-0.33%
After-hours: Aug 15, 2025, 07:44 PM EDT
Avadel Pharmaceuticals Cash Flow Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Net Income | -4.92M | -5.04M | -2.63M | -13.82M | -27.34M | -28.79M | -36.27M | -64.43M | -30.78M | -27.45M | -20.15M | -63.44M | -26.42M | -22.3M | -22M | -19.58M | -13.45M |
Depreciation & Amortization | 825K | 668K | 1.03M | 437K | 541K | -18K | 595K | 601K | 588K | 586K | 401K | 247K | 259K | 201K | 197K | 199K | 218K |
Stock-Based Compensation | 4.18M | 4.13M | 5.41M | 5.46M | 5.39M | 3.52M | 3.13M | 7.64M | 1.52M | 1.93M | 1.92M | 658K | 2.5M | 2.78M | 2.36M | 2M | 1.73M |
Other Working Capital | n/a | 9.43M | 26.42M | 10.51M | -3.23M | 8.08M | 1.32M | 9.49M | -3.9M | -1.5M | 15.93M | -1.01M | -1.43M | -1.56M | 3.07M | 6.54M | -618K |
Other Non-Cash Items | n/a | 224K | -27.99M | -489K | 10.09M | 17.55M | -55K | 630K | 1.87M | 2.44M | 2.22M | 2.45M | 981K | 476K | 611K | 421K | 795K |
Deferred Income Tax | n/a | n/a | n/a | n/a | n/a | -15.94M | n/a | 13.13M | n/a | 109K | 46K | 30.19M | -4.32M | -4.34M | -5.09M | -3.69M | -2.53M |
Change in Working Capital | n/a | 8.47M | 17.28M | -9.77M | -7.57M | -4.35M | -5.62M | 10.4M | -3.43M | 7.02M | 8.76M | 15.8M | -7.04M | 678K | 2.69M | 10.5M | -10.18M |
Operating Cash Flow | -8.23M | 7.87M | -6.89M | -18.19M | -29.7M | -28.03M | -38.23M | -32.02M | -30.23M | -15.37M | -6.8M | -14.09M | -34.05M | -22.51M | -21.24M | -10.15M | -23.41M |
Capital Expenditures | n/a | n/a | 3.05 | n/a | n/a | n/a | n/a | n/a | n/a | -716K | -716K | n/a | n/a | 438.60 | 430.75 | -12.22 | -26K |
Cash Acquisitions | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -3.24M | n/a | n/a | n/a | n/a | n/a | n/a |
Purchase of Investments | -5.49M | -14.04M | -86.77M | -77.52M | -97.68M | -33.71M | -90.06M | -103.23M | -10.23M | -1.08M | -132K | -112K | -2.09M | -3.18M | -5.22M | -15.6M | -37.77M |
Sales Maturities Of Investments | 17.81M | 28.95M | 91.82M | 87.94M | 119.07M | 61.64M | 99.88M | 10.32M | 15.29M | 23.95M | 3.37M | 12.16M | 44.34M | 18.5M | 17.51M | 25.48M | 40.74M |
Other Investing Acitivies | n/a | n/a | -3.05 | n/a | 21.39M | n/a | 9.82M | -92.91M | 5.07M | 716K | 3.24M | 12.05M | 42.25M | -278.34K | -273.36K | 8.25M | 8.25M |
Investing Cash Flow | 12.32M | 14.91M | 5.06M | 10.42M | 21.39M | 27.93M | 9.82M | -92.91M | 5.07M | 22.88M | 2.52M | 12.05M | 42.25M | 15.32M | 12.29M | 18.12M | 11.19M |
Debt Repayment | n/a | n/a | n/a | n/a | n/a | -21.16M | n/a | n/a | -17.5M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Common Stock Repurchased | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Dividend Paid | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Financial Acitivies | 690K | 880K | 1.18M | 723K | 3.94M | 52K | 30.46M | -42.61M | 29K | -8.16M | 183K | -4.8M | 2.01M | -263K | 114K | n/a | 149K |
Financial Cash Flow | 690K | 880K | 1.18M | 723K | 13.19M | -21.11M | 30.46M | 91.54M | 34.44M | 6.62M | 10.71M | -4.8M | 2.01M | 263K | 114K | 70.05 | 149K |
Net Cash Flow | n/a | 22.79M | -265K | -6.95M | 4.63M | -20.64M | 1.83M | -33.41M | 9.41M | 13.27M | 6.59M | -6.75M | 10.16M | -7.46M | -8.97M | 7.97M | -12.55M |
Free Cash Flow | -8.23M | 7.87M | -6.89M | -18.19M | -29.7M | -28.03M | -38.23M | -32.02M | -30.23M | -16.08M | -7.52M | -14.09M | -34.05M | -22.51M | -21.24M | -10.15M | -23.44M |